12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Oncode funds project on clinical implementation of the MeD-seq assay
Oncode created the clinical Proof-of-Concept fund (cPoC) to support the clinical translation of Oncode’s fundamental research. We are pleased to announce that the 11th grant within the cPoC programme has been awarded to Oncode Investigator Joost Gribnau (Erasmus MC). Together with colleagues, he will work on the clinical implementation of their recently developed MeD-seq assay. The goal of the project is to deliver proof of concept of the clinical applicability of their MeD-seq assay, which is able to detect tumor-specific epigenetic patterns in the circulating cell-free DNA in the blood of patients. The researchers will evaluate whether this assay can predict early recurrence in colorectal cancer patients with surgically removable liver metastases.
A crisis calls for community: how three Oncode Investigators help find solutions for COVID-19
For more than half a year now, finding solutions to solve the current COVID-19 crisis is a priority - not only for the Netherlands, but for the entire world. With labs closed and the entire country in lockdown, the urgency and the pressure became almost tangible. In the midst of the chaos, Oncode Investigators Marvin Tanenbaum, Hans Clevers (both Hubrecht Institute) and Lude Franke (UMC Groningen) decided to put their knowledge and skills to good use.
Oncode Institute appoints Alain Kummer as its new Managing Director
Oncode Institute announced today that its Supervisory Board has appointed Alain Kummer as Managing Director per September 1st, 2020. On the same day, Ton Rijnders, Oncode’s General Director, will step down from his position. As of September 1st, the new Oncode Managing Board will consist of Geert Kops (Scientific Director and Head of the Institute), Chris De Jonghe (Valorization Director) and Alain Kummer (Managing Director).